search

Active clinical trials for "Von Willebrand Diseases"

Results 41-50 of 89

IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

The purpose of this study is to determine the efficacy and safety of rhIL-11 when given subcutaneously in adults with type 1 von Willebrand disease undergoing elective surgery or major dental procedure. Efficacy will be measured by estimated blood loss, and frequency and severity of bleeding and transfusion requirement during and after surgery. Safety will be measured by the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.

Terminated20 enrollment criteria

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With...

vonWillebrand's Disease

The main objectives of the study were to compare the pharmacokinetics (PK) of Optivate® and Haemate P® in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, VWF:CBA and Factor VIII assays. to compare the clinical tolerance and safety of these two treatments after single IV infusions in subjects with VWD.

Completed2 enrollment criteria

Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement...

Acquired Von Willebrand Disease Secondary to Severe Aortic StenosisHeye´s Syndrome1 more

Acquired Von Willebrand disease (type 2A) has been described in patients with severe aortic stenosis, the association of aortic stenosis and Digestive bleeding due to this phenomena has received the name of Heye´s syndrome. We propose that administering Desmopressin (DDAVP) in patients scheduled to aortic valve replacement surgery will reduce blood loss and transfusion rate. this was a pilot study

Completed6 enrollment criteria

Extension Study of Biostate in Subjects With Von Willebrand Disease

Von Willebrand Disease

The aim of the Von Willebrand Disease (VWD) therapy is to treat and prevent bleeding episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low or abnormal Von Willebrand Factor (VWF) and/or Factor VIII (FVIII) levels. The long-term efficacy and safety of a VWF/FVIII concentrate, Biostate, will be investigated in children, adolescents, and adults with VWD in whom treatment with a VWF product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.

Completed10 enrollment criteria

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

The aim of this study is to assess the pharmacokinetics (PK), efficacy, and safety of Biostate® in subjects with Von Willebrand Disease (VWD). Pharmacokinetic Component: PK parameters will be determined from a subgroup of subjects. Subjects who complete the PK component will subsequently continue in the efficacy component of the study, either continuing on a previously established prophylaxis regimen or continuing to receive on-demand treatment with the occurrence of non-surgical bleeding (NSB) events. Efficacy Component: Three treatment arms are defined for the efficacy component of the study. (1) Subjects who are currently being treated on a set prophylaxis regimen with a VWF product at the time of study entry will be enrolled in the "Prophylaxis" arm. (2) Subjects not being treated on a set prophylaxis regimen at the time of study entry who require a VWF product for the treatment of NSB events will be enrolled in the "On-demand" arm and commence using Biostate in the treatment of NSB events. (3) Subjects enrolled in the "On-demand" arm have the possibility to enter the "Cross-over to Prophylaxis" arm to receive an additional 12 months of prophylactic treatment.

Completed16 enrollment criteria

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

vonWillebrand DiseaseHemophilia1 more

The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia therapy option in women with an underlying bleeding disorder. We anticipate that Tranexamic Acid may be a beneficial choice for controlling menorrhagia in bleeding disorder patients.

Completed7 enrollment criteria

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical...

Von Willebrand DiseaseBlood Coagulation Disorders2 more

The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.

Completed16 enrollment criteria

Low VW Activity in Adolescent HMB

Von Willebrand Factor Deficiency

This is a research study for patients diagnosed with heavy menstrual bleeding (HMB) and low Von Willebrand Factor (VWF). Menstruation, also known as a period, is the regular discharge of blood and tissues from the uterus. HMB is having a heavier amount of discharge during menstrual period. Low Von Willebrand Factor means that the participant has lower level of a blood protein that is important for clotting of blood and so, the participant is at a higher risk for bleeding. The purpose of this project is to study the genetic differences of adolescent females with HMB and low VWF activity and compare the genetic differences with their bleeding manifestations, response to medications and outcome.

Active8 enrollment criteria

rVWF IN PROPHYLAXIS

Von Willebrand Disease

The purpose of this phase 3 study is to investigate the efficacy and safety, including immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics (PK), health related quality of life (HRQoL) and pharmacoeconomics of prophylactic treatment with recombinant von Willebrand factor (rVWF) (vonicog alfa) in adult participants with severe von Willebrand disease (VWD).

Completed34 enrollment criteria

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

Prevent Bleeding in Major Surgery

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Completed7 enrollment criteria
1...456...9

Need Help? Contact our team!


We'll reach out to this number within 24 hrs